Brain Cancer Therapeutics Market, by Indication (Glioblastoma, Meningioma, Pituitary Tumors, and Others), by Treatment Type (Targeted Therapy, Chemotherapy, Immunotherapy, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and O

Brain Cancer Therapeutics Market, by Indication (Glioblastoma, Meningioma, Pituitary Tumors, and Others), by Treatment Type (Targeted Therapy, Chemotherapy, Immunotherapy, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Cancer is one of the most prevalent and fatal chronic disorders with a high mortality rate. Throughout our lives, healthy cells in our bodies divide and replace themselves in a controlled fashion. Cancer starts when a cell is altered and it multiplies out of control. A tumor is formed when such abnormal cells grow to form a mass. Cancer cells grow to form tumor that interfere with brain functions such as muscle control, memory, sensation, and other normal bodily functions. Symptoms of brain cancer vary but often include weakness, difficulty walking, dizziness, seizures, and headaches.
The brain and spinal column make up the central nervous system (CNS), where all important functions are controlled. These functions include thought, body movements, and speech. This means that when a tumor grows in the CNS, it can affect a person's thought processes or the way they move or talk. A treatment plan is individualized and planned for each brain cancer patient depending on certain factors. The treatment plan is constructed by the doctors who are specialized in brain cancer, and treatments vary widely depending on the type of cancer, brain location of the tumor, tumor size, patient age, and the general health status of the patient. A major part of the plan is also determined by the wish of the patient.
Market Dynamics
The increasing launches of new drugs and regulatory approvals for brain cancer therapeutics are expected to drive the market growth during the forecast period. For instance, in June 2021, Food and Drug Administration (FDA) has granted fast track designation to TVAX Biomedical, Inc. for TVI-Brain-1, an adoptive T cell therapy for the treatment of glioblastoma multiforme. TVI-Brain-1 (TVAX Biomedical) is an autologous, vaccine-enhanced adoptive T-cell therapy consisting a proprietary vaccine pretreatment to create cancer-specific T cells and an activated antitumor T-cell treatment. The Fast Track Designation was supported by positive Phase 2 clinical data in addition to extensive preclinical and Phase 1 safety studies.
Key features of the study:
This report provides an in-depth analysis of the global brain cancer therapeutics market, market size (US$ Mn), and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global brain cancer therapeutics market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Pfizer Inc., GlaxoSmithKline PLC, Novartis AG, Johnson & Johnson, Merck & Co, Bayer AG, and Bristol-Myers Squibb Company
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global brain cancer therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global brain cancer therapeutics market
Detailed Segmentation:
Global Brain Cancer Therapeutics Market, By Indication:
Glioblastoma
Meningioma
Pituitary Tumors
Others
Global Brain Cancer Therapeutics Market, By Treatment Type:
Targeted Therapy
Chemotherapy
Immunotherapy
Others
Global Brain Cancer Therapeutics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Brain Cancer Therapeutics Market, By Region:
North America
Indication
Glioblastoma
Meningioma
Pituitary Tumors
Others
Treatment Type
Targeted Therapy
Chemotherapy
Immunotherapy
Others
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
U.S.
Canada
Latin America
Indication
Glioblastoma
Meningioma
Pituitary Tumors
Others
Treatment Type
Targeted Therapy
Chemotherapy
Immunotherapy
Others
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Indication
Glioblastoma
Meningioma
Pituitary Tumors
Others
Treatment Type
Targeted Therapy
Chemotherapy
Immunotherapy
Others
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
Indication
Glioblastoma
Meningioma
Pituitary Tumors
Others
Treatment Type
Targeted Therapy
Chemotherapy
Immunotherapy
Others
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
Indication
Glioblastoma
Meningioma
Pituitary Tumors
Others
Treatment Type
Targeted Therapy
Chemotherapy
Immunotherapy
Others
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
GCC
Israel
Rest of Middle East
Africa
Indication
Glioblastoma
Meningioma
Pituitary Tumors
Others
Treatment Type
Targeted Therapy
Chemotherapy
Immunotherapy
Others
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region
South Africa
Central Africa
North Africa
Company Profiles
Amgen Inc.
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Strategies
AstraZeneca PLC
F. Hoffmann-La Roche Ltd.
Pfizer Inc.
GlaxoSmithKline PLC
Novartis AG
Johnson & Johnson
Merck & Co
Bayer AG
Bristol-Myers Squibb Company
“*” marked represents similar segmentation in other categories in the respective section.